Biomedical Research Models, Inc.

WORCESTER, MA · Biotech · Acquired

RSV vaccine candidates using stabilized pre-fusion F protein antigenic sites to elicit mucosal immune responses

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · brmcro.com

Sector: Biotech
Headquarters: WORCESTER, MA
Latest Form D: $1.5M offered, Jun 2011
Total capital: $9.4M

Federal grants: $3.3M; 6 awards · 2015–2017; Rank in peer group#299 of 514
Private capital raised: $1.5M; 1 Form D · last Jun 2011; 184 months since last filing
Federal contracts: $4.6M; 1 award · Health and Human S; Rank in Biotech#85 of 4373
Granted patents: 1; 9 pending · first 2017; Rank in peer group#186 of 514

Capital timeline

Latest events

Jun 2017Federal grantHealth and Human S · Phase I · Optimization of a mucosal RSV vaccine$228K
Jan 2017Federal grantHealth and Human S · Phase I · Selection of a device for intranasal administration of a mucosal vaccine for HSV$300K
Jan 2017Federal grantHealth and Human S · Phase I · Selection of a device for intranasal administration of a mucosal vaccine for HSV-2$300K
Jul 2016Federal grantHealth and Human S · Phase I · Optimization of a mucosal RSV vaccine$442K
May 2016Federal grantHealth and Human S · Phase II · Advancing a Mucosal HSV-2 Vaccine Towards Clinical Trials$1M
May 2015Federal grantHealth and Human S · Phase II · Advancing a Mucosal HSV-2 Vaccine Towards Clinical Trials$999K
Jun 2011Offering registeredForm D · SEC · 1st filing$1.5M

Show 1 earlier federal award

Jul 2006Federal contractHealth and Human S · Biomedical (basic)$4.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

59months

from Biomedical Research Models, Inc.’s first federal award to its first private round.

First federal award · Jul 2006: Health and Human S · $4.6M
First Form D · Jun 2011: $1.5M · 1st Form D
Awards before first raise: 1 award

An association in public records, not a cause or a prediction.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#186 · top 36%
Linked publications#95 · top 18%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Dennis L. GuberskiExecutive Officer, DirectorNamed in SEC Form D filings
Paul L. DiNinoDirectorNamed in SEC Form D filings
R. Duffy L. DufresneDirectorNamed in SEC Form D filings
R. Norman C. PetersDirectorNamed in SEC Form D filings
Robert L. HardingDirectorNamed in SEC Form D filings
Steve C. MirickDirectorNamed in SEC Form D filings

Show all 7 people

Thomas C. LynchExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 10

Jul 12, 2018PendingNovel Mucosal Vaccination Approach For Herpes Simplex Virus TYPE-2USPTOApplication 15674929
Jan 11, 2018PendingTherapeutic Vaccines For Treating Herpes Simplex Virus TYPE-2 InfectionsUSPTOApplication 15713019
Sep 14, 2017PendingNovel Mucosal Vaccination Approach For Herpes Simplex Virus TYPE-2USPTOApplication 15299876

Show all 10 patent records

Novel Mucosal Vaccination Approach For Herpes Simplex Virus TYPE-2Jul 12, 2018 · Application 15674929Pending
Therapeutic Vaccines For Treating Herpes Simplex Virus TYPE-2 InfectionsJan 11, 2018 · Application 15713019Pending
Novel Mucosal Vaccination Approach For Herpes Simplex Virus TYPE-2Sep 14, 2017 · Application 15299876Pending
Therapeutic Vaccines For Treating Herpes Simplex Virus TYPE-2 InfectionsFeb 14, 2017 · US 9,566,325Granted
Novel Mucosal Vaccination Approach For Herpes Simplex Virus TYPE-2Application 15394022Pending
Therapeutic Vaccines For Treating Herpes Simplex Virus TYPE-2 InfectionsApplication 15431175Pending
Therapeutic Vaccines For Treating Herpes Simplex Virus Type 2 InfectionsApplication PCTUS2014010516Pending
A Novel Mucosal Vaccination Approach For Herpes Simplex Virus TYPE-2Application PCTUS2011027751Pending
Methods Of Cancer Treatment/prevention Using Cancer Cell-specific Surface AntigensApplication PCTUS2005038968Pending
Non-human Animal Models For Diabetic Complications And Their UsesApplication PCTUS2005029654Pending

Recent research by its founders

HBV-induced N6 methyladenosine modification of PARP1 enhanced AFB1-related DNA damage and synergistically contribute to HCC20256 cites
HAUS6 as a potential prognostic and immunological biomarker: validation from pan-cancer analysis to hepatocellular carcinoma20251 cites
The Role of MATN3 in Cancer Prognosis and Immune Infiltration Across Multiple Tumor Types20251 cites

SIGMOVIR BIOSYSTEMS, INC.Similar federal contract value in Biotech · $4.9M in contracts
MIMEDX GROUP, INC.Similar federal contract value in Biotech · $4.8M in contracts
METACLIPSE THERAPEUTICS CORPSimilar federal contract value in Biotech · $4.7M in contracts
SORRENTO THERAPEUTICS, INC.Similar federal contract value in Biotech · $4.6M in contracts
FD NEUROTECHNOLOGIES CONSULTING & SERVICES, INC.Similar federal contract value in Biotech · $4.6M in contracts
BIOLOGICAL MIMETICS, INC.Similar federal contract value in Biotech · $4.6M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.